AMDHD2 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the AMDHD2 gene has been disrupted to create a loss-of-function model for functional studies. This heterogeneous pool of edited cells, derived through CRISPR/Cas9-mediated gene targeting, enables investigation of AMDHD2-associated metabolic pathways without the confounding effects of wild-type gene expression. The polyclonal format captures a spectrum of editing events, providing a robust system for examining gene function in the context of a genetically modified human embryonic kidney background. As a population-level knockout resource, these cells are well-suited for downstream assays that require bulk cellular material, including metabolomic profiling and enzymatic analysis.
The host cell line, HEK293T, is a widely utilized human embryonic kidney derivative that constitutively expresses the SV40 large T-antigen, facilitating high transfection efficiency and robust protein production. This line is extensively employed for recombinant protein expression, viral packaging, and metabolic engineering due to its rapid growth and well-characterized genetic tractability. The introduction of an AMDHD2 knockout into this background allows researchers to dissect the gene??s role in a human cellular context that retains key metabolic machinery while offering the experimental versatility required for systematic biochemical and functional inquiries.
AMDHD2 encodes a putative amidohydrolase enzyme, which based on sequence homology is predicted to participate in the catabolism of histidine or nucleotides. Within the histidine degradation pathway, it may function alongside histidine ammonia-lyase, urocanase, and imidazolonepropionase to process imidazole-containing intermediates. Although direct interactors, upstream regulators, and downstream targets remain uncharacterized, the disruption of AMDHD2 is expected to impair flux through this pathway, leading to alterations in metabolite profiles such as the accumulation of urocanate or imidazolone propionate. The loss of this amidohydrolase activity provides a means to evaluate its contribution to nitrogen metabolism and to identify potential functional redundancies or compensatory mechanisms.
In the HEK293T environment, knockout of AMDHD2 creates a metabolic perturbation that can be probed with high-resolution analytical techniques. The absence of functional AMDHD2 may shift cellular energy and amino acid homeostasis, providing a platform to assess the enzyme??s role in histidine degradation and related metabolic networks. This model holds significance for exploring how imbalances in histidine metabolism influence overall cellular physiology, and it may serve as a surrogate for studying metabolic disorders associated with disturbances in amino acid catabolism, despite the lack of direct disease linkage.
Key research applications include metabolic enzyme characterization, functional genomics, and drug metabolism studies, where the knockout cells can be compared to wild-type counterparts. Representative experimental approaches encompass western blotting and RT-qPCR for expression analysis, LC-MS-based metabolomics to profile small-molecule intermediates, enzyme activity assays to confirm loss of function, and cell proliferation assays to gauge metabolic fitness. These cells enable the investigation of AMDHD2??s function in histidine utilization and broader amino acid processing, supporting drug discovery efforts that target metabolic vulnerabilities. For further details or technical assistance, interested parties are encouraged to contact Ascent Research.
